NCT06124131: BENEFIT-C

Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening

Completed NA Results posted Last updated 4 May 2025

What this trial tests

NA trial testing Financial incentive for colorectal cancer screening in Health Behavior in 50 participants. Completed in 25 March 2024.

Timeline

11 November 2023

Primary endpoint
25 March 2024

25 March 2024

Quick facts

Lead sponsor	Tulane University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	screening
Enrollment	50
Start date	11 November 2023
Primary completion	25 March 2024
Estimated completion	25 March 2024
Sites	1 location across United States

Drugs / interventions tested

• Financial incentive for colorectal cancer screening
• Financial incentive for flu shot
• Financial incentive for COVID-19 shot

Conditions studied

• Health Behavior — all drugs for Health Behavior →
• Colorectal Cancer — all drugs for Colorectal Cancer →
• Influenza — all drugs for Influenza →
• COVID-19 — all drugs for COVID-19 →

Sponsor

Tulane University

Who can join

Adults 45 to 75, any sex, with Health Behavior or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Difference in Percent of Participants Completing Colorectal Cancer Screening Between Study Arms Primary · Two months

Completion of colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test as documented in electronic health record within two months of study enrollment

Group	Value	95% CI
Full Financial Incentives	17
Partial Financial Incentives	8

Difference in Percent of Participants Completing COVID-19 Shot Between Study Arms Secondary · Two months

Completion of COVID-19 shot as documented in electronic health record within two months of study enrollment

Group	Value	95% CI
Full Financial Incentives	1
Partial Financial Incentives	0

Difference in Percent of Participants Completing Flu Shot Between Study Arms Secondary · Two months

Completion of flu shot as documented in electronic health record within two months of study enrollment

Group	Value	95% CI
Full Financial Incentives	9
Partial Financial Incentives	10

Difference in Percent of Participants Completing at Least One of the Following Services Between Study Arms: Colorectal Cancer Screening, COVID-19 Shot, Flu Shot Secondary · Two months

Completion of colorectal cancer screening (colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test), COVID-19 shot, \*OR\* flu shot as documented in electronic health record within two months of study enrollment

Group	Value	95% CI
Full Financial Incentives	20
Partial Financial Incentives	13

Difference in Percent of Participants Completing All Three Services Between Study Arms: Colorectal Cancer Screening, COVID-19 Shot, Flu Shot Secondary · Two months

Completion of colorectal cancer screening (colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test), COVID-19 shot, \*AND\* flu shot as documented in electronic health record within two months of study enrollment

Group	Value	95% CI
Full Financial Incentives	1
Partial Financial Incentives	0

Number of Patients Reached for Recruitment Secondary · Three months

Number of patients reached for recruitment

Group	Value	95% CI
Recruitment Sample	107

Number of Patients Assessed for Eligibility Secondary · Three months

Number of patients assessed for eligibility

Group	Value	95% CI
Reachable Sample	93

Number of Patients Consented and Randomized Secondary · Three months

Number of patients consented and randomized

Group	Value	95% CI
Eligible Sample	50

Number of Patients Who Receive the Outreach Call Intervention Secondary · Three months

Number of patients who receive the outreach call intervention

Group	Value	95% CI
Full Financial Incentives	25
Partial Financial Incentives	25

Sponsor's own description

The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. The main questions it aims to answer are:

* Do patient financial incentives for completing colorectal cancer screening increase screening completion?
* Does a patient financial incentive for colorectal cancer screening offered alongside patient financial incentives for COVID-19 and flu shots increase completion of those shots?

Participants who are due for colorectal cancer screening will receive telephone outreach from primary care staff who will offer a stool-based colorectal cancer screening. Participants will be randomly assigned to either Group 1 or Group 2. Group 1 participants will be offered financial incentives for completing COVID-19 and flu shots within 2 months of enrollment. Group 2 participants will be offered financial incentives for completing a COVID-19 shot, a flu shot, and colorectal cancer screening within 2 months of enrollment.

Researchers will compare to see if completion of a COVID-19 shot, a flu shot, and colorectal cancer screening is different between the two groups.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Current Progress in Clinical Research in Secondary Prevention and Early Detection of Colorectal Cancer.
   Partyka O, Pajewska M, Czerw A, Deptała A, et al · · 2025 · cited 2× · PMID 39941735 · DOI 10.3390/cancers17030367
2. Building Engagement Using Financial Incentives for Colorectal Cancer Screening (BENEFIT‐C) in a Rural Louisiana Federally Qualified Health Center
   Perry L, Peacock E, LeBlanc A, Williams L, et al · · 2025